- Scrip
- >>Business
- >>Deals
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Philadelphia-based Aevi Genomic Medicine Inc. acquired the right on 7 August to exercise an exclusive global development and commercialization...